急性缺血性卒中直接取栓与桥接治疗研究进展  

Research progress of direct thrombectomy and bridging therapy for acute ischemic stroke

作　　者：卓娜[1] 樊宇 韦建琦 王璐[1] 张菊林 ZHUO Na;FAN Yu;WEI Jianqi(Affiliated Baotou Clinical College of Inner Mongolia Medical University,Baotou 014040,China)

机构地区：[1]内蒙古医科大学包头临床学院,014040

出　　处：《临床神经病学杂志》2024年第5期375-379,共5页Journal of Clinical Neurology

基　　金：内蒙古自治区科技计划项目(2021GG0223);内蒙古自治区科技创新引导项目(CXYD2022BT02)。

摘　　要：血管内机械取栓是急性缺血性卒中治疗最重要的进展,早期及时的血管内机械取栓可以带来显著的临床获益。采取静脉溶栓后进行血管内介入治疗的治疗方式为桥接治疗。传统的桥接治疗有可能存在时间延误、出血风险增加等局限性。近年来,随着多项大型随机对照试验陆续完成,可否绕过静脉溶栓直接进行机械取栓成为卒中治疗领域关注的热点。另外第三代溶栓药物替奈普酶具有更便捷的给药方式,也为桥接治疗提供了新思路。本文围绕已完成的相关研究,针对直接机械取栓治疗与桥接治疗的获益及风险进行比较和分析,旨为急性缺血性卒中患者选择正确诊疗手段提供参考。Endovascular mechanical thrombectomy is an important progress in the treatment of acute ischemic stroke,and early and timely endovascular mechanical thrombectomy can provide significant clinical benefits.The treatment mode of endovascular therapy after intravenous thrombolysis is bridging therapy,while the traditional bridging therapy may have limitations such as time delay and increased bleeding risk.In recent years,with the completion of several large scale randomized controlled trial,whether to bypass intravenous thrombolysis and directly perform mechanical thrombectomy has become a hot topic in the field of stroke treatment.In addition,the third generation of thrombolytic drug Tenecteplase has a more convenient way of administration,it also provides new ideas for bridging therapy.This article compares and analyzes the benefits and risks of direct mechanical thrombectomy therapy and bridging therapy based on relevant research that has been completed,aiming to provide reference for the correct selection of treatment methods for acute ischemic stroke patients.

关 键 词：机械取栓 桥接治疗 替奈普酶 急性缺血性卒中 

分 类 号：R743.3[医药卫生—神经病学与精神病学]